Lowest Price Guaranteed From USD 3,999
In my opinion, the global market for drug delivery technologies is still in its infancy and I expect a significant growth once technologies under evaluation are clinically validated and begin to generate revenues. Until this takes place, the market is likely to be driven by technology access fees, and upfront and milestone payments.
-- CEO, a California-based mid-sized technology developer
The drug delivery technologies market for biologics is estimated to be worth $227 million in 2019 and is expected to grow at CAGR of 23% during the forecast period. Given their high target specificity and limited toxicity compared to small molecule drugs, biotherapeutics have revolutionized treatment paradigms across a myriad of clinical conditions, including metabolic disorders, cancers, neurological disorders and autoimmune disorders. In fact, the extent of growth of such therapies can be gauged from the fact that more than 300 biopharmaceuticals have been approved between 2002 and 2018. In 2018, over 15 biological license applications (BLA) received approval. Previously, in 2017, 12 new biologics were approved by the US FDA, which included antibodies (9), antibody-drug conjugates (1), and enzymes (2). Such products are inherently complex, and their full potential continues to remain untapped owing to an array of concerns associated with their development, manufacturing and administration. Specifically, the challenges associated with the delivery of such drugs can be attributed to their large molecular weight, short half-lives, and instability in the gastrointestinal (GI) tract and intestinal lumen. Owing to their susceptibility to enzymatic degradation, the parenteral route of administration is considered to be the most acceptable mode of delivery, enabling such drugs to directly enter systemic circulation. However, parenteral administration often requires patients to visit healthcare centers / clinics for dosing. As a result, non-adherence to prescribed therapeutic regimens is rampant among end-users.
Despite these challenges, the demand for biologics is high because of their favorable safety profiles, greater systemic compatibility and fewer side effects. As a result, medical researchers and therapy developers are actively attempting to identify and exploit alternative delivery strategies for such products; examples include aerosol generation systems, lipid nanoparticles, DNA-based delivery technologies, and brain shuttles (designed to facilitate increased drug penetration across the elusive blood-brain barrier). Currently, several biopharmaceutical companies have undertaken initiatives to develop cell-specific drug delivery technologies and have superior formulation technologies, imparting improved release properties to drugs being delivered. Consequently, pharmaceutical developers are likely to witness a rise in available options for the delivery of their respective products in the foreseen future.
Examples of key companies engaged in drug delivery technologies market for biologics (which have also been profiled in this market report; the complete list of companies is available in the full report) include Aphios, Arbutus Biopharma, Camurus, ConjuChem, InnoCore Pharmaceuticals and LATITUDE Pharmaceuticals. This market report includes an easily searchable excel database of all the companies providing drug delivery technologies for delivery of proteins, antibodies and nucleic acids, worldwide.
The “Drug Delivery Technologies Market for Delivery of Proteins, Antibodies and Nucleic Acids, 2019-2030” market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the drug delivery technologies market.
The market research report features an in-depth analysis, highlighting:
The key objective of drug delivery technologies market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for drug delivery technologies market during the forecast period. Based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the evolution of the market over the forecast period 2018-2030. The market report features likely distribution of the current and forecasted opportunity across the [A] type of therapeutic area (oncology and non-oncology), [B] route of administration (parenteral and non-parenteral), [C] key contributing technologies and [D] key geographical regions (North America, Europe, Asia Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this market research report were influenced by discussions conducted with multiple stakeholders in drug delivery technologies market. The market report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names):
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.